SMMT
The PFS headline investors wanted
Summit Therapeutics just got a shiny new data point for ivonescimab, and the headline is pretty simple: the drug combo did better than the control arm in its global Phase 3 HARMONi trial. In plain English, the treatment kept EGFR-mutated lung cancer patients from progressing longer — the kind of thing biotech investors love to see because it helps de-risk the story.
The Lancet Oncology published the primary analysis, and the numbers did the heavy lifting:
- median progression-free survival came in at 6.8 months vs. 4.4 months for placebo plus chemo
- hazard ratio was 0.52, which is the clinical-trial equivalent of saying, “yeah, that’s a real win”
- independent reviewers confirmed the result, and the benefit showed up across preplanned subgroups
The catch? Overall survival is still the cliffhanger
The broader survival picture is still cooking. Summit said the primary overall survival analysis showed a positive trend, but not statistical significance yet. That’s biotech for: the market got something good, but the final season hasn’t aired.
There’s also a manageable safety profile, which matters a lot here because even good cancer drugs can get tripped up if the side effects look scary. Severe treatment-related hemorrhage events were reported in less than 1% of patients, which is about as close as biotech gets to saying, “don’t panic.”
Why the stock still has more chapters ahead
The next catalysts are already on the calendar. Summit plans to present more data at the 2026 World Conference on Lung Cancer on September 15th, 2026, and the FDA has set a November 14th, 2026 action date for the company’s BLA.
A few moving pieces to keep on your radar:
- updated OS data from a June 2026 cutoff still showed a positive trend
- Western patients had a 0.76 hazard ratio in that follow-up analysis
- China approved ivonescimab in a different lung cancer setting through partner Akeso, which adds more international validation to the asset
Big picture: this is the kind of update that can keep a biotech bull case alive without fully closing the book. The PFS data are encouraging, the FDA date is real, and now investors are basically waiting to see whether the next data drop turns “promising” into “approved.”